选择性醛糖还原酶抑制剂AT-001治疗糖尿病心肌病的随机试验
ARISE-HF试验纳入691例糖尿病心肌病且峰值摄氧量降低的患者,随机接受安慰剂或递增剂量AT-001每日两次,主要终点为15个月峰值摄氧量比例变化。结果显示高剂量AT-001组峰值摄氧量下降-0.01 mL/kg/min,安慰剂组下降-0.31 mL/kg/min,组间差异0.30(P=0.19),未达统计学显著。
要点
- AT-001治疗15个月未显著改善糖尿病心肌病患者的运动能力。
- 安慰剂组峰值摄氧量较基线显著下降,高剂量AT-001组下降无统计学意义。
- 未使用SGLT2i或GLP-1RA的预设亚组中组间差异0.62 mL/kg/min(P=0.04,交互P=0.10)。
核心结论
- 在糖尿病心肌病合并运动能力受损的患者中,AT-001治疗15个月未较安慰剂显著改善运动能力。
研究设计与样本
- 多中心随机对照试验,691例符合纳入排除标准的糖尿病心肌病患者随机接受安慰剂或递增剂量AT-001每日两次。
- 按入组地区、心肺运动试验结果及是否使用SGLT2i或GLP-1RA进行分层。
- 主要终点为基线至15个月峰值摄氧量的比例变化。
主要发现
- 平均年龄67.5±7.2岁,女性占50.4%。
- 15个月时安慰剂组峰值摄氧量下降-0.31 mL/kg/min(较基线P=0.005),高剂量AT-001组下降-0.01 mL/kg/min(P=0.21)。
- 安慰剂与高剂量AT-001组间峰值摄氧量差异为0.30(P=0.19)。
- 基线未使用SGLT2i或GLP-1RA的预设亚组中,15个月时安慰剂与高剂量AT-001组间峰值摄氧量差异为0.62 mL/kg/min(P=0.04;交互P=0.10)。
临床怎么用
- 对于糖尿病心肌病合并运动能力受损患者,AT-001未显示较安慰剂显著改善运动能力的证据。
- 未使用SGLT2i或GLP-1RA患者的亚组结果需谨慎解读,交互检验未达显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Progression to symptomatic heart failure is a complication of type 2 diabetes; heart failure onset in this setting is commonly preceded by deterioration in exercise capacity. OBJECTIVES: This study sought to determine whether AT-001, a highly selective aldose reductase inhibitor, can stabilize exercise capacity among individuals with diabetic cardiomyopathy (DbCM) and reduced peak oxygen uptake (Vo2). METHODS: A total of 691 individuals with DbCM meeting inclusion and exclusion criteria were randomized to receive placebo or ascending doses of AT-001 twice daily. Stratification at inclusion included region of enrollment, cardiopulmonary exercise test results, and use of sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists. The primary endpoint was proportional change in peak Vo2 from baseline to 15 months. Subgroup analyses included measures of disease severity and stratification variables. RESULTS: The mean age was 67.5 ± 7.2 years, and 50.4% of participants were women. By 15 months, peak Vo2 fell in the placebo-treated patients by -0.31 mL/kg/min (P = 0.005 compared to baseline), whereas in those receiving high-dose AT-001, peak Vo2 fell by -0.01 mL/kg/min (P = 0.21); the difference in peak Vo2 between placebo and high-dose AT-001 was 0.30 (P = 0.19). In prespecified subgroup analyses among those not receiving sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists at baseline, the difference between peak Vo2 in placebo vs high-dose AT-001 at 15 months was 0.62 mL/kg/min (P = 0.04; interaction P = 0.10). CONCLUSIONS: Among individuals with DbCM and impaired exercise capacity, treatment with AT-001 for 15 months did not result in significantly better exercise capacity compared with placebo. (Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy [ARISE-HF]; NCT04083339).
引用
- Januzzi JL, Butler J, Del Prato S, et al. Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy. J Am Coll Cardiol. 2024. PMID: 38597864. doi:10.1016/j.jacc.2024.03.380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。